Clinical trials: Biliary Cancers
HER2-positive Breast Cancer, Cervical Cancer
Tucatinib Continuation Study
The purpose of this protocol is to give continued access to tucatinib eligible participants. It also enables ongoing safety follow-up for those who continue to benefit from the study treatment.
- Conditions
- HER2-positive Breast Cancer, Cervical Cancer, Biliary Tract Neoplasms, Urothelial Cancer
- Trial name
- NCT07768358
- Testing
- tucatinib
- Volunteers
- 175 people
- Sponsor
- Pfizer
Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc)
Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
The purpose of this study is to evaluate the anti-tumor efficacy of daraxonrasib monotherapy in patients with unresectable or advanced/metastatic, KRAS-mutant BTC who have progressed on or are intolerant of 1st line systemic…
- Conditions
- Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
- Trial name
- NCT07793253
- Testing
- Daraxonrasib
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HER2-positive Advanced Solid Tumor
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
- Trial name
- NCT05150691
- Testing
- DB-1303/BNT323, Pertuzumab Injection, Ritonavir
- Where
- 102 sites in United States, Australia and 4 more
- Volunteers
- 796 people
- Sponsor
- DualityBio Inc.
Biliary Tract Neoplasms
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1).
- Trial name
- TOPAZ-1 (NCT03875235)
- Testing
- Durvalumab
- Where
- 126 sites in United States, Argentina and 15 more
- Volunteers
- 810 people
- Sponsor
- AstraZeneca
Biliary Tract Cancer (BTC)
Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma
This is a prospective, single-arm, phase II clinical study. Patients with advanced cholangiocarcinoma harboring FGFR2 fusions or rearrangements who have either not previously received standard therapy or have experienced…
- Trial name
- NCT07786766
- Testing
- Pemigatinb, PD-1 inhibitors, Chemotherapy
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Haitao Zhao, MD
Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma
BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
This phase Ib/II trial tests the safety and side effects of BMS-986504 in combination with pemetrexed and how well the combination works in treating patients with solid tumors with MTAP deletion and that has spread from where it…
- Conditions
- Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Malignant Digestive System Neoplasm
- Trial name
- NCT07594626
- Testing
- Biospecimen Collection, Computed Tomography, Pemetrexed
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Northwestern University
Liver Cancer, Esophageal Cancer
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease…
- Conditions
- Liver Cancer, Esophageal Cancer, Colorectal Cancer, Lung Adenocarcinoma
- Trial name
- TEG (NCT05517811)
- Testing
- TEG indices
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Hepatocellular Carcinoma, Biliary Tract Cancer
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.
- Trial name
- NCT05775159
- Testing
- Volrustomig, Bevacizumab, Lenvatinib
- Where
- 46 sites in United States, China and 7 more
- Volunteers
- 294 people
- Sponsor
- AstraZeneca
Biliary Tract Tumors
QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors
QL1706 Combined with Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors：A Single - Arm, Open - Label, Multi - Center, Prospective Phase II Clinical Trial (Spring Study)
- Trial name
- Spring (NCT06892925)
- Testing
- QL1706
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Uterine Neoplasms, Uterine Cervical Neoplasms
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the…
- Conditions
- Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms
- Trial name
- NCT04579380
- Testing
- tucatinib, trastuzumab, fulvestrant
- Where
- 108 sites in United States, Belgium and 6 more
- Volunteers
- 217 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Hepatocellular Carcinoma, Pancreas Cancer
Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy
This clinical trial tests the feasibility and how well a scheduled meditation intervention works to improve postoperative outcomes such as pain, anxiety, insomnia, stress and mobility for patients undergoing pancreatectomy.
- Conditions
- Hepatocellular Carcinoma, Pancreas Cancer, Biliary Tract Neoplasms
- Trial name
- NCT07608458
- Testing
- Actigraphy, Online Mindfulness Meditation, Smartphone Application-based Intervention
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- City of Hope Medical Center
Pancreas Cancer, Biliary Tract Cancer
Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers
The primary objective of this study is to evaluate the ability to recruit and retain participants, and to successfully conduct a psilocybin-based protocol, for a study of the treatment of distress related to stage IV or…
- Conditions
- Pancreas Cancer, Biliary Tract Cancer, Psychological Distress, Gastrointestinal Cancer
- Trial name
- NCT05220046
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Nebraska
Biliary Tract Carcinoma, Cholangiocarcinoma
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
This is a phase 2 study of gemcitabine, cisplatin, zimberelimab (AB122) and quemliclustat (AB680) in subjects with untreated advanced biliary tract cancers (BTC).
- Conditions
- Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
- Trial name
- NCT06048133
- Testing
- Gemcitabine, Cisplatin, Zimberelimab
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Nataliya Uboha
Biliary Cancer Metastatic
mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line
In second line with advanced or recurrent biliary tract cancer refractory to first line gemcitabine plus cisplatin,efficacy of mFOLFOX/FOLFIRI vs mFOLFOX will be evaluated at randomized phase 2 trial.
- Trial name
- NCT07062536
- Testing
- Oxaliplatin, 5FU, leucovorin, Oxaliplatin, 5FU, leucovorin/Irinotecan , 5FU, leucovorin,
- Where
- 11 sites in South Korea
- Volunteers
- 130 people
- Sponsor
- Seoul National University Bundang Hospital
Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer
This phase II/III trial studies how well the addition of ivonescimab to standard chemotherapy (gemcitabine and cisplatin) works when compared to usual chemotherapy and immunotherapy (durvalumab or pembrolizumab) in treating…
- Conditions
- Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma, Locally Advanced Intrahepatic Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Adenocarcinoma
- Trial name
- NCT07765433
- Testing
- Biospecimen Collection, Cisplatin, Computed Tomography
- Volunteers
- 336 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Liver Cancer, Pancreatic Cancer
YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies
This study aims to determine the safety and maximum tolerated dose (MTD) of YMN-136 vaccine through a dose escalation trial, and to investigate whether YMN-136 vaccine can assist in the treatment of patients with advanced…
- Conditions
- Liver Cancer, Pancreatic Cancer, Biliary Tract Cancer (BTC)
- Trial name
- NCT07763301
- Testing
- YMN-136 vaccine
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC)
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
This is a global, multi-center, open-label, Phase I/II first-in-human study of XNW27011 monotherapy as an investigational product (IP) in patients with locally advanced and/or metastatic solid tumors who have failed or are…
- Conditions
- Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic
- Trial name
- NCT06792435
- Testing
- XNW27011
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma
AB122 Platform Study
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
- Conditions
- Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT04999761
- Testing
- AB122, TAS-116, TAS-120
- Where
- 9 sites in Japan
- Volunteers
- 917 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.
- Conditions
- Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT07021066
- Testing
- BL-M05D1
- Where
- 11 sites in United States
- Volunteers
- 160 people
- Sponsor
- SystImmune Inc.